生物
免疫系统
间质细胞
肿瘤微环境
利基
多细胞生物
癌症研究
生态位
细胞
免疫学
生态学
遗传学
栖息地
作者
Tancredi Massimo Pentimalli,Simon Schallenberg,Daniel León-Periñán,Ivano Legnini,Ilan Theurillat,Gwendolin Thomas,Anastasiya Boltengagen,Sonja Fritzsche,Jose Nimo,Lukas Ruff,Gabriel Dernbach,Philipp Jurmeister,Sarah Murphy,Mark Gregory,Yan Liang,Michelangelo Cordenonsi,Stefano Piccolo,Fabian Coscia,Andrew Woehler,Nikos Karaiskos,Frederick Klauschen,Nikolaus Rajewsky
标识
DOI:10.1101/2023.05.10.539644
摘要
ABSTRACT Cells live and interact in three-dimensional (3D) cellular neighborhoods. However, histology and spatial omics methods mostly focus on 2D tissue sections. Here we present a 3D spatial atlas of a routine clinical sample, an aggressive human lung carcinoma, by combining in situ quantification of 960 cancer-related genes across ∼340,000 cells with measurements of tissue-mechanical components. 3D cellular neighborhoods subdivided the tumor microenvironment into tumor, stromal, and immune multicellular niches. Interestingly, pseudotime analysis suggested that pro-invasive epithelial-to-mesenchymal transition (EMT), detected in stroma-infiltrating tumor cells, already occurred in one region at the tumor surface. There, myofibroblasts and macrophages specifically co-localized with pre-invasive tumor cells and their multicellular molecular signature identified patients with shorter survival. Moreover, cytotoxic T-cells did not infiltrate this niche but colocalized with inhibitory dendritic and regulatory T cells. Importantly, systematic scoring of cell-cell interactions in 3D neighborhoods highlighted niche-specific signaling networks accompanying tumor invasion and immune escape. Compared to 2D, 3D neighborhoods improved the characterization of immune niches by identifying dendritic niches, capturing the 3D extension of T-cell niches and boosting the quantification of niche-specific cell-cell interactions, including druggable immune checkpoints. We believe that 3D communication analyses can improve the design of clinical studies investigating personalized, combination immuno-oncology therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI